Sirolimus for Injection (Albumin-bound)

DRUG3 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

HR+/HER2- Advanced/Metastatic Breast CancerMalignant Solid Tumors

Phase 1

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Malignant Solid Tumors

Start: 2022-10-31End: 2024-12-31Target: 270Updated: 2022-08-23

Phase 2

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Active, not recruitingNCT06957379

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.HR+/HER2- Advanced/Metastatic Breast Cancer

Start: 2024-02-29End: 2025-12-31Updated: 2025-05-04

Phase 3

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Not yet recruitingNCT06929325

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.HR+/HER2- Advanced/Metastatic Breast Cancer

Start: 2025-04-30End: 2027-12-31Target: 312Updated: 2025-04-16

Related Papers

Abstract PD10-10: A Multicenter, Open-Label, Phase 2 Study of nab-Sirolimus (HB1901) Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer Following Standard Therapy Failure

Clinical Cancer Research2026-02-17